Clinical Trial Detail

NCT ID NCT02528877
Title Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

myelofibrosis

acute myeloid leukemia

Therapies

Fludarabine + Melphalan

Ruxolitinib + Sirolimus + Tacrolimus

Age Groups: adult

No variant requirements are available.